%0 Journal Article %T Prognostic Usefulness of Myocardial Work in Patients With Heart Failure and Reduced Ejection Fraction Treated by Sacubitril/Valsartan %+ CHU Pontchaillou [Rennes] %+ Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes] %A Bouali, Y. %A Donal, Erwan %A Gallard, A. %A Laurin, C. %A Hubert, A. %A Bidaut, A. %A Leclercq, Christophe %A Galli, Elena %< avec comité de lecture %@ 0002-9149 %J American Journal of Cardiology %I Elsevier %V 125 %N 12 %P 1856-1862 %8 2020 %D 2020 %R 10.1016/j.amjcard.2020.03.031 %M 32305222 %Z Life Sciences [q-bio]/Bioengineering %Z Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemJournal articles %X The noninvasive assessment of myocardial work (MW) by pressure-strain loops analysis (PSL) is a relative new tool for the evaluation of myocardial performance. Sacubitril/Valsartan is a treatment for heart failure with reduced ejection fraction (HFrEF) which has a spectacular effect on the reduction of cardiovascular events (major adverse cardiovascular events [MACEs]). This study aimed to evaluate the short- and medium-term effect of Sacubitril/Valsartan treatment on MW parameters and the prognostic value of MW in this specific group of patients. Seventy-nine patients with HFrEF (mean age 66 ± 12 years; LV ejection fraction 28% ± 9%) were prospectively included in the study and treated with Sacubitril/Valsartan. Echocardiographic examination was performed at baseline, and after 6- and 12-month of therapy with Sacubitril/Valsartan. Sacubitril/Valsartan significantly increased myocardial constructive work (CW) (1023 ± 449 vs 1424 ± 484 mm Hg%, p <0.0001) and myocardial work efficiency (WE) [87 (78to 90) vs 90 (86 to 95), p <0.0001]. During FU (2.6 ± 0.9 years), MACEs occurred in 13 (16%) patients. After correction for LV size, LV ejection fraction and WE, global myocardial constructive work (CW) was the only predictor of MACEs [hazard ratio [HR] 0.99 (0.99 to 1.00), p = 0.04]. A CW <910 mm Hg identified patients at particularly increase risk of MACEs [HR 11.09 (1.45 to 98.94), p = 0.002, log-rank test p <0.0001]. In conclusion, in patients with HFrEF who receive a comprehensive background beta-blocker and mineral-corticoid receptor antagonist therapy, Sacubitril/Valsartan induces a significant improvement of myocardial CW and WE. In this population, the estimation of CW before the initiation of Sacubitril/Valsartan allows the prediction of MACEs. %G English %2 https://univ-rennes.hal.science/hal-02865291/document %2 https://univ-rennes.hal.science/hal-02865291/file/Bouali%20et%20al-2020-Prognostic%20Usefulness%20of%20Myocardial%20Work%20in%20Patients%20with%20Heart%20Failure%20and.pdf %L hal-02865291 %U https://univ-rennes.hal.science/hal-02865291 %~ LTSI %~ CARDIO %~ HL %~ STATS-UR1 %~ UR1-MATH-STIC %~ UNIV-RENNES %~ UR1-MATH-NUM %~ UR1-BIO-SA %~ TEST3-HALCNRS